281 related articles for article (PubMed ID: 17166540)
1. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry.
Pugach P; Marozsan AJ; Ketas TJ; Landes EL; Moore JP; Kuhmann SE
Virology; 2007 Apr; 361(1):212-28. PubMed ID: 17166540
[TBL] [Abstract][Full Text] [Related]
2. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
[TBL] [Abstract][Full Text] [Related]
3. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.
Kuhmann SE; Pugach P; Kunstman KJ; Taylor J; Stanfield RL; Snyder A; Strizki JM; Riley J; Baroudy BM; Wilson IA; Korber BT; Wolinsky SM; Moore JP
J Virol; 2004 Mar; 78(6):2790-807. PubMed ID: 14990699
[TBL] [Abstract][Full Text] [Related]
4. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
[TBL] [Abstract][Full Text] [Related]
5. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.
Murga JD; Franti M; Pevear DC; Maddon PJ; Olson WC
Antimicrob Agents Chemother; 2006 Oct; 50(10):3289-96. PubMed ID: 17005807
[TBL] [Abstract][Full Text] [Related]
6. Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands.
Ketas TJ; Kuhmann SE; Palmer A; Zurita J; He W; Ahuja SK; Klasse PJ; Moore JP
Virology; 2007 Aug; 364(2):281-90. PubMed ID: 17428518
[TBL] [Abstract][Full Text] [Related]
7. Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.
Henrich TJ; Lewine NR; Lee SH; Rao SS; Berro R; Gulick RM; Moore JP; Tsibris AM; Kuritzkes DR
Antimicrob Agents Chemother; 2012 Apr; 56(4):1931-5. PubMed ID: 22252820
[TBL] [Abstract][Full Text] [Related]
8. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
[TBL] [Abstract][Full Text] [Related]
9. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
[TBL] [Abstract][Full Text] [Related]
10. Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities.
Pugach P; Ray N; Klasse PJ; Ketas TJ; Michael E; Doms RW; Lee B; Moore JP
Virology; 2009 May; 387(2):296-302. PubMed ID: 19303620
[TBL] [Abstract][Full Text] [Related]
11. Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.
Berro R; Klasse PJ; Lascano D; Flegler A; Nagashima KA; Sanders RW; Sakmar TP; Hope TJ; Moore JP
J Virol; 2011 Aug; 85(16):8227-40. PubMed ID: 21680525
[TBL] [Abstract][Full Text] [Related]
12. Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants.
Berro R; Yasmeen A; Abrol R; Trzaskowski B; Abi-Habib S; Grunbeck A; Lascano D; Goddard WA; Klasse PJ; Sakmar TP; Moore JP
J Virol; 2013 Jun; 87(12):6569-81. PubMed ID: 23468486
[TBL] [Abstract][Full Text] [Related]
13. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1.
Strizki JM; Tremblay C; Xu S; Wojcik L; Wagner N; Gonsiorek W; Hipkin RW; Chou CC; Pugliese-Sivo C; Xiao Y; Tagat JR; Cox K; Priestley T; Sorota S; Huang W; Hirsch M; Reyes GR; Baroudy BM
Antimicrob Agents Chemother; 2005 Dec; 49(12):4911-9. PubMed ID: 16304152
[TBL] [Abstract][Full Text] [Related]
14. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.
Tsamis F; Gavrilov S; Kajumo F; Seibert C; Kuhmann S; Ketas T; Trkola A; Palani A; Clader JW; Tagat JR; McCombie S; Baroudy B; Moore JP; Sakmar TP; Dragic T
J Virol; 2003 May; 77(9):5201-8. PubMed ID: 12692222
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.
Putcharoen O; Lee SH; Henrich TJ; Hu Z; Vanichanan J; Coakley E; Greaves W; Gulick RM; Kuritzkes DR; Tsibris AM
J Virol; 2012 Jan; 86(2):1119-28. PubMed ID: 22090117
[TBL] [Abstract][Full Text] [Related]
17. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.
Martín J; LaBranche CC; González-Scarano F
J Virol; 2001 Apr; 75(8):3568-80. PubMed ID: 11264346
[TBL] [Abstract][Full Text] [Related]
18. Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.
Lobritz MA; Ratcliff AN; Marozsan AJ; Dudley DM; Tilton JC; Arts EJ
Antimicrob Agents Chemother; 2013 Jun; 57(6):2640-50. PubMed ID: 23529732
[TBL] [Abstract][Full Text] [Related]
19. Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.
Nedellec R; Coetzer M; Lederman MM; Offord RE; Hartley O; Mosier DE
PLoS One; 2011; 6(7):e22020. PubMed ID: 21760945
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use.
Trkola A; Kuhmann SE; Strizki JM; Maxwell E; Ketas T; Morgan T; Pugach P; Xu S; Wojcik L; Tagat J; Palani A; Shapiro S; Clader JW; McCombie S; Reyes GR; Baroudy BM; Moore JP
Proc Natl Acad Sci U S A; 2002 Jan; 99(1):395-400. PubMed ID: 11782552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
